according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Oxfendazole / Oxyclozanide Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Veterinary medicine

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B H360FD: May damage fertility. May damage the

unborn child.

Specific target organ toxicity - single ex-

posure, Category 2

H371: May cause damage to organs.

Specific target organ toxicity - repeated H373: May ca

exposure, Category 2

H373: May cause damage to organs through pro-

longed or repeated exposure.

Short-term (acute) aquatic hazard, Cate-

gory 1

H400: Very toxic to aquatic life.

H410: Very toxic to aquatic life with long lasting

Long-term (chronic) aquatic hazard, Cat-

effects.

egory 1

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 7978723-00009
 Date of first issue: 19.03.2021

Hazard pictograms



¥2

Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn

child.

H371 May cause damage to organs.

H373 May cause damage to organs through prolonged

or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor.

P391 Collect spillage.

Hazardous components which must be listed on the label:

oxyclozanide oxfendazole

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
Onemical name	OAO NO.	Classification	Concentiation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

VersionRevision Date:SDS Number:Date of last issue: 06.04.20242.328.09.20247978723-00009Date of first issue: 19.03.2021

	EC-No. Index-No. Registration number		(% w/w)
oxyclozanide	2277-92-1 218-904-0	Repr. 2; H361d STOT SE 2; H371 (Central nervous system) STOT RE 2; H373 (Brain, Liver) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 30 - < 50
		M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	
oxfendazole	53716-50-0 258-714-5	Repr. 1B; H360FD STOT RE 2; H373 (Liver, Testis) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 20 - < 25
		M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 1	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage fertility. May damage the unborn child.

May cause damage to organs.

May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Chlorine compounds Nitrogen oxides (NOx)

Metal oxides

Oxides of phosphorus

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 7978723-00009
 Date of first issue: 19.03.2021

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 7978723-00009
 Date of first issue: 19.03.2021

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific 4 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

dust)

Basis: IE OEL

10 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable

dust)

Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
oxyclozanide	2277-92-1	TWA	0.4 mg/m3 (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm ²	Internal
Starch, oxidized	65996-62-5	OELV - 8 hrs (TWA) (Dust)	1 mg/m3	IE OEL
	Further information: Chemical agents which following exposure may cause sensitisation of the respiratory tract and lead to asthma, rhinitis or extrinsic allergic alveolitis			
Magnesium stea- rate	557-04-0	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 7978723-00009
 Date of first issue: 19.03.2021

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : white to off-white, light cream, cream

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

Relative density : No data available

Density : 0.88 g/cm³

Relative vapour density : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 7978723-00009
 Date of first issue: 19.03.2021

Components:

oxyclozanide:

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg

Target Organs: Central nervous system

Acute toxicity (other routes of :

administration)

LDLo (sheep): 10 mg/kg

Application Route: Intravenous

oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg

LD50 (Dog): 1,600 mg/kg

LD50 (sheep): 250 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.3 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

Components:

oxyclozanide:

Exposure routes Dermal

Remarks Not classified due to lack of data.

Germ cell mutagenicity

Not classified based on available information.

Components:

oxyclozanide:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Test Type: Mouse Lymphoma

Result: positive

Genotoxicity in vivo Test Type: Micronucleus test

> Species: Mouse Application Route: Oral

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

oxfendazole:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow Genotoxicity in vivo

cytogenetic test, chromosomal analysis)

Species: Mouse Application Route: Oral Result: positive

Carcinogenicity

Not classified based on available information.

Components:

oxyclozanide:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rat
Application Route : Oral
Exposure time : 1 Years

Symptoms : No adverse effects

Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

Symptoms : No adverse effects

Target Organs : Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat, male and female

Application Route: Oral

General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal

and postnatal development Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body

weight

Symptoms: Reduced body weight, No effects on embryofoetal

and postnatal development Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: LOAEL: 75 - 100 mg/kg body

weight

Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body

weight

Result: No fetotoxicity, No teratogenic effects, No effects on

fertility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 7978723-00009
 Date of first issue: 19.03.2021

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 100 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: NOAEL: 32 mg/kg body weight

Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 17 mg/kg body weight

Target Organs: Testes Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.9 mg/kg body weight

Target Organs: Liver

Result: No effects on fertility

Test Type: Fertility Species: Mouse Application Route: Oral

Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight

Target Organs: Testes Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Fetal effects

Test Type: Embryo-foetal development

Species: Rat

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-foetal toxicity, foetal abnormalities

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 0.625 mg/kg body weight

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

May cause damage to organs.

Components:

oxyclozanide:

Exposure routes : Oral

Target Organs : Central nervous system
Assessment : May cause damage to organs.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

oxyclozanide:

Target Organs : Brain, Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

oxfendazole:

Exposure routes : Oral

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

oxyclozanide:

Species : Rat NOAEL : 9 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 7978723-00009
 Date of first issue: 19.03.2021

LOAEL : 44.5 mg/kg Application Route : Oral Exposure time : 3 Months

Target Organs : Brain, Liver, spleen, Adrenal gland

Symptoms : Liver effects

Species : Dog
NOAEL : 5 mg/kg
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Brain, Liver

Symptoms : blood effects, alteration in liver enzymes

oxfendazole:

Species : Rat
NOAEL : 11 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Target Organs : Blood, Liver, Testis

Species : Rat
NOAEL : 3.8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Liver, Testis

Species : Mouse
NOAEL : 750 mg/kg
Application Route : Oral
Exposure time : 1 Months
Target Organs : Liver

Species : Mouse
NOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Liver

Species : Dog
NOAEL : 6 mg/kg
Application Route : Oral
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 11 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Target Organs : Lymph nodes, thymus gland

Species : Dog

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Date of last issue: 06.04.2024 Version Revision Date: SDS Number: 2.3 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

NOAEL 13.5 mg/kg **Application Route** Oral 12 Months Exposure time Target Organs Liver

Aspiration toxicity

Not classified based on available information.

Components:

oxyclozanide: Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:

The substance/mixture does not contain components consid-Assessment

> ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

oxyclozanide:

Ingestion Symptoms: May cause, Gastrointestinal disturbance, Central

nervous system depression

SECTION 12: Ecological information

12.1 Toxicity

Components:

oxyclozanide:

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.69 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

M-Factor (Acute aquatic tox- :

icity)

M-Factor (Chronic aquatic

toxicity)

: 1

oxfendazole:

LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l Toxicity to fish

Exposure time: 96 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.059 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

10

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.023 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

: 1

12.2 Persistence and degradability

Components:

oxyclozanide:

Stability in water : Hydrolysis: 50 %(156 d)

Method: OECD Test Guideline 111

oxfendazole:

Stability in water : Hydrolysis: < 5 %(4 d)

12.3 Bioaccumulative potential

Components:

oxyclozanide:

Partition coefficient: n- : log Pow: 3.99

octanol/water pH: 7

Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n-

octanol/water

log Pow: 1.95

17 / 23

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

12.4 Mobility in soil

Components:

oxyclozanide:

Distribution among environ- : log Koc: 4.83

mental compartments Method: OECD Test Guideline 106

oxfendazole:

Distribution among environ-

mental compartments

log Koc: 3.2

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3077

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, oxyclozanide)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, oxyclozanide)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, oxyclozanide)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, oxyclozanide)

IATA : Environmentally hazardous substance, solid, n.o.s.

(oxfendazole, oxyclozanide)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III Classification Code : M7

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

Hazard Identification Number : 90 Labels : 9

IMDG

Packing group : III Labels : 9

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956 Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone : Not applicable

layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2
E1 ENVIRONMENTAL 100 t 200 t

HAZARDS

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H360FD : May damage fertility. May damage the unborn child.

H361d : Suspected of damaging the unborn child. H371 : May cause damage to organs if swallowed.

H373 : May cause damage to organs through prolonged or repeated

exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 7978723-00009 Date of first issue: 19.03.2021

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level: NOELR - No Observable Effect Loading Rate: NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Repr. 1B H360FD Calculation method STOT SE 2 H371 Calculation method

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxfendazole / Oxyclozanide Formulation

Version 2.3	Revision Date: 28.09.2024	SDS Number: 7978723-00009	Date of last issue: 06.04.2024 Date of first issue: 19.03.2021	
STOT	RE 2	H373	Calculation method	
Aquati	ic Acute 1	H400	Calculation method	
Aquati	ic Chronic 1	H410	Calculation method	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN